Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

LY4005130

Other · developed by ELI LILLY &

Phase 2 Most advanced trial
LLY Developer
1 Registered trials

What is LY4005130?

LY4005130 is an investigational drug studied in Vitiligo, Non-Segmental Vitiligo (NSV).

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07533019 Phase 2 Vitiligo Recruiting LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-Segmental Vitiligo (NSV)Vitiligo

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Follow LLY, the company behind LY4005130

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.